UNBS 5162: an antineoplastic agent; structure in first source [MeSH]
| ID Source | ID |
|---|---|
| PubMed CID | 16048966 |
| CHEMBL ID | 4303530 |
| SCHEMBL ID | 4188839 |
| SCHEMBL ID | 4188846 |
| MeSH ID | M0524402 |
| Synonym |
|---|
| S8869 |
| CS-3379 |
| HY-16509 |
| unbs5162 |
| urea, n-(2-(2-(dimethylamino)ethyl)-2,3-dihydro-1,3-dioxo-1h-benz(de)isoquinolin-5-yl)- |
| unii-jy9jf7d78n |
| unbs-5162 , |
| jy9jf7d78n , |
| 956590-23-1 |
| SCHEMBL4188839 |
| SCHEMBL4188846 |
| 1-(2-(2-(dimethylamino)ethyl)-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinolin-5-yl)urea |
| unbs 5162 |
| J-690410 |
| AKOS026750504 |
| EX-A460 |
| n-{2-[2-(dimethylamino)ethyl]-1,3-dioxo-2,3-dihydro-1h-benzo[de]isoquinolin-5-yl}urea |
| WCKZRLOUKYFJDY-UHFFFAOYSA-N , |
| BCP23948 |
| unbs5162;unbs 5162 |
| F17359 |
| [2-[2-(dimethylamino)ethyl]-1,3-dioxobenzo[de]isoquinolin-5-yl]urea |
| mfcd22380608 |
| FT-0700422 |
| BS-17981 |
| CHEMBL4303530 |
| Q27281742 |
| A858960 |
| AC-35979 |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|---|---|---|---|
| PPM1D protein | Homo sapiens (human) | Potency | 7.3876 | AID1347411 |
| Interferon beta | Homo sapiens (human) | Potency | 7.3876 | AID1347411 |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1347412 | qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7 ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (14.29%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (85.71%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| urea | isourea; monocarboxylic acid amide; one-carbon compound | Daphnia magna metabolite; Escherichia coli metabolite; fertilizer; flour treatment agent; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite | 2008 | 2018 | 8.5 | high | 1 | 0 | 0 | 1 | 5 | 0 | |
| naphthalimides | 2008 | 2018 | 8.5 | high | 1 | 0 | 0 | 1 | 5 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adverse Drug Event | 0 | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Cancer of Colon | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Cancer of Esophagus | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Cancer of Lung | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Cancer of Prostate | 0 | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Carcinoma, Epidermoid | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Carcinoma, Non-Small Cell Lung | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Carcinoma, Non-Small-Cell Lung | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Carcinoma, Squamous Cell | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Colonic Neoplasms | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Disease Models, Animal | 0 | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 | |
| Drug-Related Side Effects and Adverse Reactions | 0 | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Esophageal Neoplasms | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Esophageal Squamous Cell Carcinoma | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Germinoblastoma | 0 | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Lung Neoplasms | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Lymphoma | 0 | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Malignant Melanoma | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Melanoma | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Metastase | 0 | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Neoplasm Metastasis | 0 | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 | |
| Prostatic Neoplasms | 0 | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |